Leadership changes at Valeant as three more execs depart

14 December 2016
valeant-big

Troubled Valeant Pharmaceuticals International (TSX: VRX) has announced the departure of three executives, as the business continues to restructure at the close of a punishing 2016.

The Canadian company has already lost more than 80% of its market value since the year began, amid debt woes, the Philidor scandal, and a criminal investigation by the US Securities and Exchange Commission into its accounting and pricing practices.

"We continue working toward a recovery of our core prescription dermatology business"

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical